“The consequences of antimicrobial resistance are real and growing, while at the same time, companies are leaving the commercial space,” said Dr. Morris. “New and accessible treatments are critical to preserve the life-saving effectiveness of antimicrobials for everyone in Canada, and particularly the most vulnerable.”

The report advocates for a novel compensation framework – subscription pull incentives – as an alternative to invigorate research, development and commercialization of new antimicrobials. This model provides drug manufacturers with a reliable return on investment, addressing shortcomings within traditional market mechanisms.